Actos News
Most Popular Actos Story
Nexium, Actos, or Diovan? Analysts try to ID Ranbaxy's 3 sacrifices
Now that the dust has settled around Ranbaxy Laboratories' deal with the U.S. Justice Department, three missing bits of information are looming large. Which three first-to-file exclusivity rights Read more...
Latest Headlines
- December 1, 2011
- October 24, 2011
- July 22, 2011
- June 27, 2011
- June 24, 2011
- June 16, 2011
- June 10, 2011
- June 9, 2011
- March 18, 2011
- September 29, 2010
- September 24, 2010
- September 20, 2010
- August 25, 2010
- July 22, 2010
- July 21, 2010
- July 16, 2010
- July 14, 2010
- July 12, 2010
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
